Mucosolvan*20cps 75mg Prolonged Release,Mucosolvan*20cps 75mg Rilascio Prolungato,BOEHRINGER INGELHEIM IT.SPA

ACTIVE substances: Ambroxol hydrochloride. Excipients: stearyl alcohol, carnauba wax, crospovidone, magnesium stearate; rcolo activity: gelatin, titanium dioxide, iron oxide yellow, iron oxide r bone. INDICATIONS: Treatment of secretion disorders in broncopolmona diseases, acute and chronic. CONTRAINDICATIONS/EFF.SECONDARY: Hypersensitivity to the active substance or to any of the excipients; serious impairment of liver and kidney function; the drug should not be prescribed to children. DOSAGE: It is recommended to adhere to the following dosages unless otherwise prescribed in the prescription. In the dolovo: 2 capsules per day, taken in the morning after breakfast for 8 days (attack therapy). Subsequently, the dosage will be r idol with 1 capsule per day, taken in the morning, before termites and treatment. The capsules should not be opened or chewed, but should be swallowed whole with plenty of water or other liquids. And make co in capsules can be taken regardless of food. Introduction of mind-blowing to patients with diabetes. The presence of granules containing the active ingredient in the feces does not make sense, since they have already released the drug with p taste through the digestive system. The capsules should not be used in children. For acute respiratory illnesses, consult a doctor if symptoms do not improve or worsen during treatment with the product. STORAGE: Do not store above 30 degrees C. WARNING: Ambroxol hydrochloride should be prescribed with caution in patients nti carriers of peptic ulcer disease. In very rare cases, serious skin lesions such as Stevens-Johnson syndrome and toxic epidermal necrolysis (NET) have been observed while taking expectorants such as ambroxol. Most of them can be explained by the severity of the underlying disease or by drug filters at the same time. Also in the initial stages of Stevens-Johnson syndrome or toxic epidermal necrolysis (NET), NTI patients may initially experience non-specific symptoms similar to those affected, such as fever, chills, rhinitis, to sse and sore throat. Because of these symptoms, it is misleading and can be treated symptomatically with coughs and colds. If new lesions of the skin or mucous membranes occur, consult a doctor immediately and discontinue ion treatment precautions with ambroxol hydrochloride. In case of kidney function, the drug can be used only after consultation with a doctor. INTERACTIONS: As a result of the administration of ambroxol, concentrations of ant ibiotics (amoxicillin, cefuroxime, erythromycin) in the secretions of bronchopolmonari and in saliva of additional results. Ortaca interactions with other drugs have not been reported. SIDE EFFECTS: Adverse reactions are listed below by classification s hysteresis and organs and by frequency, in the following categories: very common (>= 1/10); general (>= 1/100, = 1/1.000, = 1/10.000,